« Back
Home /
CBR-2092

CBR-2092

Item no.	TMO-T26963-5mg
Manufacturer	TargetMol
CASRN	922717-97-3
Amount	5 mg
Quantity options	100 mg 500 mg 5 mg
Category	Inhibitors & Compound Libraries Small Molecules
Type	Inhibitor
Specific against	other
Purity	0,98
Smiles	CO[C@H]1\C=C/O[C@@]2(C)Oc3c(C2=O)c2c(O)c(C=NN4CCC(CC4)N(C)C4(CC4)[C@@H]4CCN(C4)c4c(F)cn5c(c4C)c(cc(C(O)=O)c5=O)C4CC4)c(NC(=O)\C(C)=C/C=C\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)c(O)c2c(O)c3C \|c:3,66,68\|
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	TNP 2092, CBR2092, TNP2092, TNP-2092
Shipping Condition	Cool pack
Available
Shipping Temperature	cool pack
Storage Conditions	-20°
Molecular Weight	1205, 388
Target names or alias	TNP-2092 , CBR2092 , TNP2092 , TNP 2092
Description	CBR-2092 is a DNA-directed RNA polymerase and DNA topoisomerase inhibitor. CBR-2092 exhibited rifampin-like potency as an inhibitor of RNA polymerase, was an equipotent (balanced) inhibitor of DNA gyrase and DNA topoisomerase IV, and retained activity against a prevalent quinolone-resistant variant. Studies of mutant strains that exhibited reduced susceptibility to CBR-2092 further substantiated RNA polymerase as the primary cellular target of CBR-2092, with DNA gyrase and DNA topoisomerase IV being secondary and tertiary targets, respectively, in strains exhibiting preexisting rifampin resistance.
Pathways	Others

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

Request safety datasheet

Simple Order Order Subscription

Amount: 5 mg

available

Compare

Add to wishlist

Get an offer

Request delivery time

Ask a technical question